

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 258 473 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
20.11.2002 Bulletin 2002/47

(21) Application number: 01906177.9

(22) Date of filing: 21.02.2001

(51) Int Cl.⁷: **C07C 233/29**, C07C 233/55,
C07C 255/60, C07C 231/12,
C07C 231/02, C07C 253/30,
C07C 323/63, C07C 323/62,
C07C 319/20, C07D 215/06,
C07D 213/75, C07D 333/40,
C07D 213/80, C07D 263/34,
C07D 215/12, A61K 31/196,
A61K 31/47, A61K 31/44,
A61K 31/381, A61K 31/421,
A61K 31/4402

(86) International application number:
PCT/JP01/01263

(87) International publication number:
WO 01/062708 (30.08.2001 Gazette 2001/35)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.02.2000 JP 2000044424

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
Osaka-shi, Osaka 541-8526 (JP)


(72) Inventors:
• **TANI, Kousuke** Ono Pharmaceutical Co., Ltd.
Shimamotocho Mishima-gun
Osaka 618-8585 (JP)

• **KOBAYASHI, Kaoru**
Ono Pharmaceutical Co., Ltd.
Shimamotocho Mishima-gun Osaka 618-8585
(JP)
• **MARUYAMA, Takayuki**
Ono Pharmaceutical Co., Ltd.
Shimamotocho Mishima-gun Osaka 618-8585
(JP)

(74) Representative: **Henkel, Feiler, Hänzeli**
Möhlstrasse 37
81675 München (DE)

(54) **BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT**

(57) An agent comprising the benzoic acid of formula (I)



EP 1 258 473 A1

, wherein A, B, R⁶, R⁷ are carbocyclic ring, heterocyclic ring, etc.; R¹ is hydroxy etc.; R², R³, R⁴ are alkyl etc.; R⁵, D, E are alkylene, etc.; G is oxygen etc., as active ingredient.


The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

Description

Technical Field

[0001] The present invention relates to benzoic acid derivatives.

[0002] More specifically, the present invention relates to a benzoic acid derivative of formula (I)



, wherein all symbols have the same meanings as hereafter described, a process for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient.

Background

[0003] Prostaglandin E₂ (abbreviated as PGE₂) has been known as a metabolite in the arachidonic acid cascade. It has been known that PGE₂ possesses cyto-protective activity, uterine contractile activity, a pain-inducing effect, a promoting effect on digestive peristalsis, an awakening effect, a suppressive effect on gastric acid secretion, hypotensive activity, and diuretic activity.

[0004] In the recent study, it was found that PGE₂ receptor was divided into some subtypes which possess different physical roles from each other. At present, four receptor subtypes are known and they are called EP₁, EP₂, EP₃ and EP₄ (Negishi M. et al, J. Lipid Mediators Cell Signaling 12, 379-391 (1995)) respectively.

[0005] Among these subtypes, EP₄ receptor was believed to be involved in suppression of TNF-α production and induction of IL-10 production. So the compounds which can bind to EP₄ receptor strongly and show the antagonizing activity, are useful for the prevention and/or treatment of diseases (bone diseases such as osteoporosis, rheumatoid arthritis, osteoarthritis, abnormal bone formation etc. and cancer (formation, proliferation, metastasis to organs, and to bones, hypercalcemia etc.) and systemic granuloma, immunological diseases such as ALS, multiple sclerosis, Sjögren's syndrome, systemic lupus erythematosus, AIDS etc. and allergy (conjunctivitis, rhinitis, contact dermatitis, psoriasis), atopic dermatitis, asthma, pyorrhea, gingivitis, periodontitis, neuronal cell death, Alzheimer's disease, pulmonary injury, hepatopathy, acute hepatopathy, nephritis, renal failure, myocardial ischemia, Kawasaki disease, scald, ulcerative colitis, Crohn's disease, multiple organ failure etc. Moreover, EP₄ is thought to be involved in sleeping disorder and platelet aggregation, so the compounds are considered to be useful.


[0006] On the other hand, in the specification of JP-A-51-115456, as a compound analogous to the compound of the present invention, 2-[2-(benzoylamino)phenylmethyl]benzoic acid is disclosed as a synthetic example. This application is only to disclose the process for the synthesis and nothing is described about pharmacological effect etc.

Disclosure of the Invention


[0007] The present inventors have energetically studied to find the compound which binds to EP₄ receptor specifically and show an inhibitory activity against it, to find out that the benzoic acid derivatives of formula (I) achieve the purpose and completed the present invention.

[0008] The present invention relates to

(1) a benzoic acid derivative of formula (I)



15 , wherein



are each independently, C3~7 carbocyclic ring or 5~7 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen atom,

D is C1-4 alkylene, oxygen or sulfur atom,

G is oxygen or sulfur,

E is a bond, oxygen, sulfur, C1-4 alkylene, C1-4 alkyloxy or C1-4 oxyalkyl,

R¹ is hydroxy, -OR⁹ or -NR¹⁰R¹¹, wherein R⁹ is C1-6 alkyl, and

R¹⁰ and R¹¹ are each independently, hydrogen atom or C1-6 alkyl,

R² and R³ are each independently, C1-4 alkyl, C1-4 alkoxy, halogen atom, trihalomethyl, cyano or nitro,

R⁴ is hydrogen or C1-6 alkyl,

R⁵ is a bond, C1-6 alkylene, C1-6 alkylene substituted with C1-4 alkoxy, or C3-5 cycloalkylene,

R⁶ is C5~15 carbocyclic ring or 5~15 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen,

R⁷ is hydrogen, C1-8 alkyl, C5~7 carbocyclic ring or 5~15 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen,

m and n are each independently, 0, 1, 2 or 3.

The rings represented by R⁶ and R⁷ may be substituted with C1-4 alkyl, C1-4 alkoxy, halogen, trihalomethyl, nitro, cyano or oxo,

with proviso that 2-[2-(benzoylamino)phenylmethyl]benzoic acid is excluded,

or a non-toxic salt thereof,

(2) a process for the preparation thereof and

(3) a pharmaceutical agent comprising the same as active ingredient.

Detailed description of the Invention

[0009] In the formula (I), C1-6 alkyl which R⁸, R⁹, R⁴, R¹⁰, R¹¹ represent includes, methyl, ethyl, propyl, butyl, pentyl, hexyl and isomers thereof.

[0010] In the formula (I), alkyl in C1-4 alkoxy and alkyl which R², R³, R⁵, E, R⁶, R⁷ represent includes, methyl, ethyl, propyl, butyl and isomers thereof.

[0011] In the formula (I), C1-8 alkyl which R⁷ represents includes, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.




[0012] In the formula (I), C1-4 alkylene which D and E represent include, methylene, ethylene, trimethylene, tetramethylene and isomers thereof.

[0013] In the formula (I), C1-6 alkylene which R⁵ represents include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene and isomers thereof.







[0014] In the formula (I), halogen atom which R², R³, R⁶, R⁷ represent include fluorine, chlorine, bromine and iodine.

[0015] In the formula (I), C3~5 cycloalkylene which R⁵ represents include cyclopropylene, cyclobutylene, cyclopentylene.



[0016] In the formula (I), C3~7 carbocyclic ring which A and B represent may be unsaturated or saturated, and for example the ones shown by the following formulae are included.









[0017] In the formula (I), 5-7 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen atom which A and B represent may be saturated or unsaturated, and for example the following ones shown by the following formulae are included.














[0018] In the formula (I), C5~15 carbocyclic ring which R⁶ and R⁷ represent may be saturated or unsaturated and for example, the ones shown by the following formulae are included.





[0019] In the formula (I), 5~15 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen atom which R6 and R7 represent may be saturated or unsaturated, and for example, the ones shown by the following formulae are included.





[0020] Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkenyl and alkynyl groups include straight-chain and also branched-chain ones. In addition, isomers in double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R-, S-, α -, β -isomer, enantiomer, diastereomer), optically active isomers having optical rotation (D-, L-, d-, l-isomer) polar compounds separated by chromatography (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at arbitrary ratios and racemic mixtures are included in branched-chain alkyl are included in the present invention.

[0021] In the compounds of the present invention of formula (I), the compounds described in examples and the compounds shown in the following tables 1~3 and corresponding esters and amides thereof are preferable.

Table 1
















Table 2






























Table 3




R




[Salt]

[0022] The compound of the present invention of formula (I) may be converted into a corresponding salt by known methods. Non-toxic and water-soluble salts are preferable. Appropriate salts are, salts of alkali metals (potassium, sodium, etc.), salts of alkaline-earth metals, ammonium salts, pharmaceutically acceptable organic amines (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine, etc.). The compound of the present invention of formula (I) and a salt thereof may also be converted into hydrates by known methods.

[Processes for the preparation of the compound of the present invention]

(a) Among the compound of formula (I), the compound wherein R^1 is hydroxy, i.e. the compound of formula (Ia)


, wherein all symbols have the same meaning as above, may be prepared by subjecting to hydrolysis under alkaline conditions the compound of formula (Ib)



, wherein R^{20} is C1-6 alkyl and the other symbols have the same meaning as above.

[0024] Hydrolysis under alkaline conditions is known, for example, it is carried out in a water-miscible organic solvent (e.g. ethanol, tetrahydrofuran (THF), dioxane, etc.) using an aqueous solution of alkali (e.g. sodium hydroxide, potassium hydroxide, potassium carbonate, etc.) at a temperature of $-10 \sim 90^\circ\text{C}$.

(b) Among the compound of formula (I), the compound wherein R^1 is $-\text{NR}^{10}\text{R}^{11}$, wherein all symbols have the same meaning as above, i.e. the compound of formula (Ic)




15 , wherein all symbols have the same meanings as above, may be prepared by subjecting to amidation reaction the compound of formula (Ia) and the compound of formula




, wherein all symbols have the same meaning as above.

[0025] Amidation reaction is known, for example, it is carried out in an inert organic solvent (e.g. THF, methylene chloride, benzene, acetone, acetonitrile or a mixture thereof) in the presence or absence of a tertiary amines (dimethylaminopyridine, pyridine, triethylamine, etc.), using a condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), etc.) or acid halide (oxalyl chloride, thionyl chloride, phosphorus oxychloride, etc.) at a temperature of 0 ~ 50 °C.

[0026] (c) The compound of formula (Ib) may be prepared by subjecting to amidation reaction the compound of formula (III)



40 , wherein all symbols have the same meaning as above, and the compound of formula (IV)



, wherein all symbols have the same meaning as above. Amidation reaction may be carried out by the same method as above described.

[0027] The compound of formula (III) may be prepared according to the following reaction schemes (A), (B) and (C). The compound of formula (IV) may be known per se or may be prepared by known methods.

The symbols in each reaction scheme represent the followings or the same meaning as above.


X¹, X², X³ : halogen atom;

D¹ : C1~4 alkylene;

D² : oxygen or sulfur atom


Reaction Scheme (A)

when D is alkylene:






Reaction Scheme (B)


when D is alkylene:



halogenation




1) Reduction
(2) R⁴-X³)



Reaction scheme (C)

when D is oxygen or sulfur:



[Starting materials and Reagents]

[0028] Each reaction in the above reaction schemes may be carried out by known methods. In the above reaction schemes, the compounds of formula (V), (VII), (IX), (XI) and (XII) may be known per se, or may be prepared by known

methods with ease. And the other starting materials and reagents may be known per se or may be prepared by known methods.

[0029] In each reaction in the present specification, reaction products may be purified by conventional purification techniques, e.g. by distillation under atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, or by washing or by recrystallization. Purification may be carried out after each reaction or after a series of reactions.

[Pharmacological Activities]

[0030] The compounds of the present invention of formula (I) bind strongly and show an antagonizing activity on the EP₄ subtype receptor, which is one of the PGE₂ receptors.

[0031] For example, in a standard laboratory test, such effects of the compound of the present invention were confirmed by binding assay using the cell expressing the prostanoid receptor subtypes.

(i) Binding assay using cell expressing the prostanoid receptor subtypes

[0032] The preparation of membrane fraction was carried out according to the method of Sugimoto et al [J. Biol. Chem. **267**, 6463-6466 (1992)], using CHO cell expressing prostanoid receptor subtype (mouse EP₁, EP₂, EP₃, EP₄ and human IP).

[0033] The standard assay mixture containing membrane fraction (0.5 mg/mL), [³H]-PGE₂ in a final volume of 200 µl was incubated for 1 hour at room temperature. The reaction was terminated by addition of 3 mL of ice-cold buffer. The mixture was rapidly filtered through a glass filter (GF/B) under reduced pressure. The radioactivity associated with the filter was measured by liquid scintillation counter.

[0034] K_d and B_{max} values were determined from Scatchard plots [Ann. N. Y. Acad. Sci. **51**, 660(1949)]. Non-specific binding was calculated as the amount bound in the presence of an excess (2.5 µM) of unlabeled PGE₂. In the experiment for competition of specific [³H]-PGE₂ binding by the compounds of the present invention, [³H]-PGE₂ was added at a concentration of 2.5 nM and the compound of the present invention was added at various concentrations. The following buffer was used in all reactions.

[0035] Buffer: 10 mM potassium phosphate (pH 6.0), 1 mM EDTA, 10 mM MgCl₂, 0.1 M NaCl.

[0036] The dissociation constant (K_i) (µM) of each compound was calculated by the following equation.

$$K_i = IC_{50} / (1 + ([C]/K_d))$$

[0037] The results are shown in Table 4.

Table 4

Example No.	EP ₄ K _i (µM)
2(1)	0.0027
2(15)	0.0065
4(1)	0.0105

[0038] As mentioned above, it is clear that the compounds of the present invention can bind strongly on the EP₄ subtype receptor.

(ii) EP₄ antagonizing activity assay using the cell expressing the prostanoid receptor subtypes

[0039] The preparation of CHO cell expressing prostanoid receptor subtype was carried out according to the method of Nishigaki et al [FEBS lett., **364**, 339-341(1995)]. The cells were cultured in 24-well microplates (10⁵ cells/well) for two days before experiments. After washing each well with 500 µL of MEM (minimum essential medium), thereto was added 450 µL of assay medium (MEM containing 1 mmol/L IBMX, 1%BSA), and the mixture was incubated for 10 minutes at 37 °C. Then PGE₂ alone or a combination with a test compound (50 µL) were added, and the mixture was incubated for 10 minutes at 37 °C. And reaction was terminated by addition of ice-cold TCA (10% W/V, 500 µL). This reaction mixture was freezed once (-80 °C) and thawed, and cells were harvested using a scraper. After centrifugation (13,000 r.p.m., for 3 minutes), cAMP content was measured using cAMP assay kit. That is, the supernatant (125 µL) was diluted with 500 µL of [¹²⁵I]-cAMP assay kit buffer (Amersham), and mixed with 0.5 mol/L tri-n-octylamine / chloroform solution (1 mL) was mixed. After removal of TCA from chloroform layer, cAMP content in the aqueous layer was quantified according to the method of kit manuals.

[0040] An antagonizing activity of compound (IC₅₀ value) was calculated as a inhibitory rate on the condition using 100nM PGE₂ as an agonist. This concentration of PGE₂ served a submaximal effect on cAMP production.

Table 5

EP ₄ antagonizing activity	
Example No.	EP ₄ antagonizing activity IC ₅₀ (μM)
2(1)	0.01

[0041] As mentioned above, it is clear that the compounds of the present invention show an antagonizing activity on the EP₄ subtype receptor.

[Toxicity]

[0042] The toxicity of the compounds of the formula (I) of the present invention is very low and therefore, it is confirmed that these compounds are safe for use as medicine.

Industrial applicability

[Application to Pharmaceuticals]

[0043] The compounds of the present invention of the formula (I) can bind and show the antagonizing activity on the PGE₂ receptor. Particularly, they bind to EP₄ subtype receptor and show the antagonizing activity, so they are useful for the prevention and/or treatment of bone diseases such as osteoporosis, rheumatoid arthritis, osteoarthritis, abnormal bone formation), cancer (e.g. cancer formation, cancer proliferation, cancer metastasis to organs and to bones, hypercalcemia accompanied by cancer metastasis to bones, etc.) and systemic granuloma, immunological diseases (e.g. amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjogren's syndrome, systemic lupus erythematosus, AIDS), allergy (conjunctivitis, rhinitis, contact dermatitis, psoriasis, etc.), atopy (atopic dermatitis etc.), asthma, pyorrhea, gingivitis, periodontitis, neuronal cell death, Alzheimer's disease, pulmonary injury, hepatopathy, acute hepatopathy, nephritis, renal failure, myocardial ischemia, Kawasaki disease, scald, ulcerative colitis, Crohn's disease, multiple organ failure etc. Moreover, it was thought to be involved in sleeping disorder and platelet aggregation, so the usefulness of inhibitors is expected.

[0044] For the purpose described above, the compounds of formula (I), of the present invention, non-toxic salts thereof may be normally administered systemically or topically, usually by oral or parenteral administration.

[0045] The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment, etc. In the human adult, the doses per person at a time are generally from 0.1 mg to 100 mg, by oral administration, up to several times per day, and from 0.01 mg to 10 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration between 1 and 24 hours per day into vein.

[0046] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases where doses lower than or greater than the ranges specified above may be used.

[0047] The compounds of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, injections, liniments or suppositories for parenteral administration.

[0048] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders and granules.

[0049] Capsules include hard capsules and soft capsules.

[0050] In such solid compositions, one or more of the active compound (s) are, admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone or magnesium metasilicate aluminate.

[0051] The compositions may also comprise, as is normal practice, additional substances other than inert diluents : e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, and assisting agents for dissolving such as glutamic acid, aspartic acid. The tablets or pills may, if desired, be coated with film of gastric- or enteric- coating agents (e.g. sugar, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

[0052] Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) are dissolved, suspended or emulsified in

inert diluent(s) commonly used (e.g. purified water, ethanol). Furthermore, such liquid compositions may also comprise wetting agents or suspending agents, emulsifying agents, sweetening agents, flavouring agents, perfuming agents, preserving agents etc.

[0053] Other compositions for oral administration include sprays which may be prepared by known methods, which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents such as sodium hydrogen sulfate, stabilizing agents to give isotonicity, isotonic buffer such as sodium chloride, sodium citrate, citric acid. For preparation of such spray compositions, for example, the method described in the United States Patent No. 2,868,691 or No. 3, 095, 355 may be used.

[0054] Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions or suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, plant oil such as olive oil, alcohol such as ethanol, POLYSORBATE80 (registered trade mark), etc.

[0055] Such compositions may comprise additional diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents, assisting agents such as assistant agents for dissolving (for example, glutamic acid, aspartic acid). They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile diluent for injection immediately before use.

[0056] Other compositions for parenteral administration include liquids for external use, and endemic liniments, ointments, suppositories and pessaries which comprise one or more of the active compound (s). and may be prepared by known methods.

Best Mode for carrying out the Invention

[0057] The following reference examples and examples illustrate the present invention, but do not limit the present invention.


[0058] The solvents in the parentheses show the eluting or developing solvents and the ratios of the solvents used are by volume in chromatographic separations or TLC.

[0059] The solvents in the parentheses in NMR show the solvents used in measurement.

Reference Example 1

1-nitro-2-iodo-4-chlorobenzene

[0060]



[0061] To a suspension of 2-nitro-5-chloroaniline (5.00 g) in conc. hydrochloric acid (30 ml) under cooling with ice, was added a solution of sodium nitrite (2.10 g) in water (10 ml) dropwise and the mixture was stirred for 30 minutes. Under cooling with ice, to this solution was added a solution of potassium iodide (5.30 g) in water (20 ml) dropwise and the mixture was stirred for 1 hour at room temperature. The solid that appeared was collected by filtration and was dissolved in ethyl acetate and was dried and concentrated to give a crude product of the title compound. It was purified by recrystallization from ethyl acetate-hexane to give the title compound having the following physical data (5.14 g, yellow powder).


TLC: R_f 0.69 (n-hexane : ethyl acetate = 9 : 1);

NMR(CDCl₃) : δ 8.06 (d, J = 2.2 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.47 (dd, J = 8.6, 2.2 Hz, 1H).

Reference Example 2

2-bromomethylbenzoic acid methyl ester

[0062]



[0063] To a solution of 2-methylbenzoic acid methyl ester (33.0 g) in tetrachlorocarbon (440 ml) were added N-bromosuccinimide (43.0 g) and AIBN (2,2'-azobisisobutyronitrile, 361 mg) and the mixture was refluxed for 30 minutes. The reaction mixture was cooled down to 0 °C and cinnamic acid that appeared were filtered off and the filtrate was concentrated. The residue was purified by distillation under reduced pressure to give the title compound having the following physical data (28.0 g, colorless oil).


TLC: Rf 0.65 (n-hexane : ethyl acetate = 4 : 1);

NMR(CDCl₃) : δ 7.97 (d, J = 7.4 Hz, 1H), 7.56-7.30 (m, 3H), 4.96 (s, 2H), 3.95 (s, 3H).

Reference Example 3

2-(5-chloro-2-nitrophenylmethyl)benzoic acid methyl ester

[0064]



[0065] To a suspension of zinc powder (1.50 g) in THF (7.5 ml) was added dibromoethane (catalytic amount) and the mixture was stirred for five minutes at 50 °C to activate the zinc. To this suspension was added a solution of 2-bromomethylbenzoic acid methyl ester (3.50 g; prepared in reference example 2) in THF (7.5 ml) at 0 °C slowly and the mixture was stirred for 30 minutes at the temperature to give a solution of 2-carbomethoxybenzylzinc (II) in THF.

[0066] A solution of 1-nitro-2-iodo-4-chlorobenzene (1.00 g; prepared in reference example 1), bis(dibenzylideneacetone)palladium (0) (20 mg) and 1,1'-bis(diphenylphosphino)ferrocene (20 mg) in THF (10 ml) was degassed. There-to was added 2-carbomethoxybenzyl zinc (THF solution; 6.0 ml) at room temperature and the mixture was stirred for 15 minutes at room temperature and 1 hour at 50 °C. The solution was cooled down and thereto was added a saturated aqueous solution of ammonium chloride and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, dried and was concentrated. The residue was purified by column chromatography on silica gel to give the title compound (849 mg; yellow oil) having the following physical data.


TLC: Rf 0.38 (n-hexane : ethyl acetate = 9:1);

NMR(CDCl₃) : δ 8.03 (dd, J = 7.8, 1.5 Hz, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.50 (m, 1H), 7.38 (m, 1H), 7.31 (dd, J = 8.7, 2.1 Hz, 1H), 7.17 (m, 1H), 6.96 (d, J = 2.1 Hz, 1H), 4.65 (s, 2H), 3.79 (s, 3H).

Reference Example 4

2-(2-amino-5-chlorophenylmethyl)benzoic acid methyl ester

[0067]



[0068] To a solution of 2-(2-nitro-5-chlorophenylmethyl) benzoic acid methyl ester (840 mg; prepared in reference example 3) in a mixture of acetic acid-water (5 : 1; 12 ml) was added steel powder (768 mg) and the mixture was added for 20 minutes at 80 °C. The suspension was poured into ice-water and was extracted with ethyl acetate. The organic layer was washed with water, a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride successively, dried, and was concentrated. The residue was purified by column chromatography on silica gel to give the title compound (363 mg) having the following physical data.


TLC: Rf 0.53 (n-hexane : ethyl acetate = 2 : 1);

NMR(CDCl₃) : δ 7.91 (dd, J = 7.6, 1.4 Hz, 1H), 7.43 (m, 1H), 7.30 (m, 1H), 7.17 (m, 1H), 7.02 (dd, J = 8.4, 2.6 Hz, 1H), 6.92 (d, J = 2.6 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 4.20 (s, 2H), 3.89 (s, 3H), 3.80 (br, 2H).

Example 1

2-[5-chloro-2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid methyl ester

[0069]



[0070] To a solution of 2-(2-amino-5-chlorophenylmethyl) benzoic acid methyl ester (339 mg; prepared in Reference Example 4) and pyridine (0.20 ml) in methylene chloride (3 ml) was added 2-(1-naphthyl)propionyl chloride (295 mg) in methylene chloride (2 ml) and the mixture was stirred for 2.5 hours at room temperature. To this solution was added a saturated aqueous solution of sodium bicarbonate and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, dried and was concentrated to give a crude product of the compound of the present invention. The residue was purified by recrystallization from ethyl acetate-hexane to give the compound of the present invention (455 mg, white powder).


TLC: Rf 0.52 (n-hexane : ethyl acetate = 3 : 1) ;

NMR(CDCl₃) : δ 8.06-7.96 (m, 3H), 7.83 (m, 1H), 7.69 (m, 1H), 7.55-7.43 (m, 3H), 7.33-7.08 (m, 5H), 6.98 (d, J = 2.2 Hz, 1H), 6.87 (dd, J = 7.6, 1.0 Hz, 1H), 4.43 (q, J = 7.0 Hz, 1H), 3.96 (d, J = 16.0 Hz, 1H), 3.72 (d, J = 16.0 Hz, 1H), 3.65 (s, 3H), 1.64 (d, J = 7.0 Hz, 3H).

Example 2

2-[5-chloro-2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0071]



[0072] To a solution of 2-[5-chloro-2-[2-(1-naphthyl) propanoylamino]phenyl methyl]benzoic acid methyl ester (440 mg; prepared in Example 1.) in methanol-dioxane (1 : 1; 8 ml) was added 2 mol/L aqueous solution of sodium hydroxide (3 ml) and the mixture was stirred for 3 hours at 50 °C. The solution was acidified with hydrochloric acid and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, dried and concentrated to give a crude crystal. It was washed with ethyl acetate-hexane to give the title compound (342 mg; white powder) having the following physical data.

TLC: Rf 0.39 (n-hexane : ethyl acetate = 1 : 1) ;

NMR(DMSO- d_6) : δ 9.65 (s, 1H), 8.19 (m, 1H), 7.91 (m, 1H), 7.86-7.76 (m, 2H), 7.56-7.27 (m, 7H), 7.23 (dd, J = 8.4, 2.4 Hz, 1H), 6.96 (d, J = 6.6 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 4.65 (q, J = 6.9 Hz, 1H), 4.27 (d, J = 16.5 Hz, 1H), 4.21 (d, J = 16.5 Hz, 1H), 1.48 (d, J = 6.9 Hz, 3H).


Example 2(1) ~ Example 2(30)

[0073] By the same procedure as described in Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 4 → Example 1 → Example 2, the compounds having the following physical data were given.

Example 2(1)

2-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl]benzoic acid

[0074]




TLC: Rf 0.61 (chloroform : methanol = 9 : 1);

NMR (DMSO- d_6) : δ 9.60 (s, 1H), 8.32-8.16 (m, 1H), 7.92-7.72 (m, 3H), 7.64-6.84 (m, 11H), 4.65 (q, J = 6.8 Hz, 1H), 4.27 (s, 2H), 1.50 (d, J = 6.8 Hz, 3H).

Example 2(2)

2-[2-[2-(2-naphthyl)propanoylamino]phenylmethyl]benzoic acid

[0075]




TLC: Rf 0.58 (chloroform : methanol = 9 : 1);

NMR(DMSO- d_6) : δ 9.56 (s, 1H), 7.94-7.72 (m, 5H), 7.58-7.40 (m, 4H), 7.38-6.86 (m, 6H), 4.29 (s, 2H), 4.04 (q, J = 7.2 Hz, 1H), 1.45 (d, J = 7.2 Hz, 3H).

Example 2(3)

2-[2-[2-(4-pentylphenyl)propanoylamino]phenylthio]benzoic acid

[0076]




TLC: Rf 0.44 (chloroform : methanol = 19 : 1);

NMR(CDCl₃) : δ 8.55 (dd, J = 8.1, 1.2 Hz, 1H), 8.23 (bs, 1H), 8.19 (m, 1H), 7.56-7.47 (m, 2H), 7.24-7.10 (m, 3H), 6.92 (s, 4H), 6.44 (m, 1H), 3.56 (q, J = 7.4 Hz, 1H), 2.49 (m, 2H), 1.59-1.19 (m, 6H), 1.44 (d, J = 7.4 Hz, 3H), 0.85 (t, J = 6.9 Hz, 3H).

Example 2(4)

2-[2-[2-(4-biphenyl)propanoylamino]phenylmethyl]benzoic acid

[0077]




TLC: Rf 0.59 (chloroform : methanol = 9 : 1);

NMR(CDC_l₃) : δ 8.01 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.67 (bs, 1H), 7.59-6.95 (m, 15H), 4.23 (d, J = 17 Hz, 1H), 4.16 (d, J = 17 Hz, 1H), 3.67 (q, J = 7.1 Hz, 1H), 1.50 (d, J = 7.1 Hz, 3H).Example 2(5)

2-[2-[2-(1,2,3,4-tetrahydroquinolin-1-yl)propanoylamino] phenylmethyl]benzoic acid

[0078]




TLC: Rf 0.48 (chloroform : methanol = 19 : 1);

NMR(DMSO-d₆) : δ 9.29 (bs, 1H), 7.81 (d, J = 7.5 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.42-7.25 (m, 2H), 7.19 (t, J = 7.7 Hz, 1H), 7.06 (t, J = 7.7 Hz, 1H), 6.97-6.84 (m, 4H), 6.63-6.47 (m, 2H), 4.46 (q, J = 7.0 Hz, 1H), 4.24 (s, 2H), 3.16 (t, J = 5.6 Hz, 2H), 2.62 (t, J = 6.5 Hz, 2H), 1.87-1.66 (m, 2H), 1.27 (d, J = 7.0 Hz, 3H).

Example 2(6)

2-[3-chloro-2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0079]




TLC: Rf 0.42 (n-hexane : ethyl acetate = 1 : 1) ;

NMR(DMSO- d_6) : δ 9.85 (s, 1H), 8.30 (m, 1H), 7.90 (m, 1H), 7.85 (dd, J = 7.8, 1.5 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.56-7.27 (m, 7H), 7.15 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 7.2 Hz, 1H), 6.81 (d, J = 7.2 Hz, 1H), 4.68 (q, J = 6.9 Hz, 1H), 4.21 (brs, 2H), 1.55 (d, J = 6.9 Hz, 3H).

Example 2(7)

2-[5-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0080]




TLC: Rf 0.52 (chloroform : methanol = 9 : 1);

NMR(DMSO- d_6) : δ 9.55 (s, 1H), 8.33 (m, 1H), 8.00 (m, 1H), 7.89 (m, 2H), 7.65-7.31 (m, 7H), 7.01 (d, J = 6.9 Hz, 1H), 6.85 (dd, J = 8.7, 2.7 Hz, 10H), 6.54 (d, J = 2.7 Hz, 1H), 4.69 (q, J = 6.9 Hz, 1H), 4.33 (d, J = 16.5 Hz, 1H), 4.26 (d, J = 16.5 Hz, 1H), 3.72 (s, 3H), 1.56 (d, J = 6.9 Hz, 3H).

Example 2(8)

2-[2-[2-(1-naphthyl)acetylamino]phenylmethyl]benzoic acid

[0081]




TLC: Rf 0.50 (chloroform : methanol = 9 : 1);

NMR(DMSO- d_6) : δ 9.80 (s, 1H), 8.13 (m, 1H), 8.02-7.87 (m, 3H), 7.62-7.38 (m, 7H), 7.26 (t, J = 6.9 Hz, 1H), 7.13 (m, 2H), 7.00 (m, 1H), 4.44 (s, 2H), 4.20 (s, 2H).

Example 2(9)

2-[2-[2-(1-naphthyl)carbonylamino]phenylmethyl]benzoic acid

[0082]




TLC: Rf 0.48 (chloroform : methanol = 9 : 1);

NMR(DMSO- d_6) : δ 10.1 (s, 1H), 8.07-7.95 (m, 3H), 7.84 (d, J = 7.5 Hz, 1H), 7.63-7.40 (m, 6H), 7.35-7.27 (m, 2H), 7.18 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 2H), 4.46 (s, 2H).

Example 2(10)

2-[3-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0083]




TLC: Rf 0.55 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 9.34 (s, 1H), 8.31 (m, 1H), 7.92-7.76 (m, 3H), 7.54-7.24 (m, 6H), 7.09 (t, J = 8.1 Hz, 1H), 6.96 (d, J = 8.1 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 6.45 (d, J = 8.1 Hz, 1H), 4.63 (q, J = 7.2 Hz, 1H), 4.20 (d, J = 15.9 Hz, 1H), 4.13 (d, J = 15.9 Hz, 1H), 3.70 (s, 3H), 1.52 (d, J = 7.2 Hz, 3H).

Example 2(11)

2-[4-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0084]




TLC: Rf 0.55 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 9.50 (s, 1H), 8.15 (m, 1H), 7.90 (m, 1H), 7.80-7.73 (m, 2H), 7.53-7.22 (m, 6H), 7.14 (d, J = 2.4 Hz, 1H), 6.89 (dd, J = 7.5, 0.9 Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 6.65 (dd, J = 8.7, 2.4 Hz, 1H), 4.62 (q, J = 6.9 Hz, 1H), 4.21 (d, J = 17.7 Hz, 1H), 4.15 (d, J = 17.7 Hz, 1H), 3.68 (s, 3H), 1.46 (d, J = 6.9 Hz, 3H).

Example 2(12)

2-[4-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0085]




TLC: Rf 0.37 (n-hexane : ethyl acetate = 1 : 1);

NMR(DMSO-d₆) : δ 9.70 (s, 1H), 8.16 (m, 1H), 7.92 (m, 1H), 7.82-7.77 (m, 2H), 7.60 (d, J = 2.1 Hz, 1H), 7.56-7.26 (m, 6H), 7.11 (dd, J = 8.4, 2.1Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 4.66 (q, J = 6.6 Hz, 1H), 4.27 (d, J = 16.8 Hz, 1H), 4.20 (d, J = 16.8 Hz, 1H), 1.48 (d, J = 6.6 Hz, 3H).

Example 2(13)

2-[6-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0086]




TLC: Rf 0.34 (n-hexane : ethyl acetate = 1 : 1);

NMR(DMSO-d₆) : δ 9.77 (brs, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.90-7.82 (m, 2H), 7.74 (dd, J = 7.5, 1.5 Hz, 1H), 7.50-7.20 (m, 9H), 6.52 (m, 1H), 4.54 (q, J = 6.9 Hz, 1H), 4.48 (brs, 2H), 1.37 (d, J = 6.9 Hz, 3H).

Example 2(14)

2-[6-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0087]




TLC: Rf 0.34 (n-hexane : ethyl acetate = 1 : 1);

NMR (DMSO-d₆) : δ 9.54 (s, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.87 (m, 1H), 7.78-7.72 (m, 2H), 7.50-7.31 (m, 4H), 7.24-7.14 (m, 3H), 7.05 (d, J = 7.8 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 6.63 (m, 1H), 4.55 (q, J = 6.9 Hz, 1H), 4.28 (brs, 2H), 3.65 (s, 3H), 1.39 (d, J = 6.9 Hz, 3H).

Example 2(15)

2-[4-[2-(1-naphthyl)propanoylamino]pyridin-3-ylmethyl] benzoic acid monohydrochloride

[0088]




TLC: Rf 0.40 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 10.52 (s, 1H), 8.64 (d, J = 6.6 Hz, 1H), 8.59 (d, J = 6.6 Hz, 1H), 8.29 (brs, 1H), 8.04 (m, 1H), 7.94 (m, 1H), 7.82 (dd, J = 7.0, 2.2 Hz, 1H), 7.72 (dd, J = 7.6, 1.4 Hz, 1H), 7.56-7.48 (m, 2H), 7.46-7.30 (m, 4H), 7.12 (d, J = 7.2 Hz, 1H), 4.93 (q, J = 6.9 Hz, 1H), 4.47 (brs, 2H), 1.52 (d, J = 6.9 Hz, 3H).

Example 2(16)

2-[2-[2-(1-naphthyl)propanoylamino]phenoxy]benzoic acid

[0089]




TLC: Rf 0.31 (n-hexane : ethyl acetate = 2 : 3);

NMR(DMSO- d_6) : δ 13.13 (br, 1H), 9.68 (s, 1H), 8.10-8.02 (m, 2H), 7.89 (m, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.72 (dd, J = 7.8, 1.8 Hz, 1H), 7.50-7.37 (m, 5H), 7.19 (m, 1H), 7.14-7.03 (m, 2H), 6.89 (dd, J = 7.8, 1.8 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 4.70 (q, J = 7.2 Hz, 1H), 1.50 (d, J = 7.2 Hz, 3H).

Example 2(17)

3-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl]thiophen-2-carboxylic acid

[0090]




TLC: Rf 0.39 (n-hexane : ethyl acetate = 1 : 2);

NMR(DMSO- d_6) : δ 13.05 (brs, 1H), 9.62 (brs, 1H), 8.25 (m, 1H), 7.92 (m, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 5.1 Hz, 1H), 7.58-7.42 (m, 4H), 7.37 (m, 1H), 7.17 (m, 1H), 7.07 (m, 1H), 7.00 (dd, J = 7.8, 1.5 Hz, 1H), 6.62 (d, J = 5.1 Hz, 1H), 4.66 (q, J = 7.2 Hz, 1H), 4.27 (d, J = 16.2 Hz, 1H), 4.20 (d, J = 16.2 Hz, 1H), 1.52 (d, J = 7.2 Hz, 3H).

Example 2(18)

(dl)-trans-2-[2-[2-(1-naphthyl)propanoylamino]phenyl methyl]cyclohexanecarboxylic acid

[0091]




TLC: Rf 0.30 (n-hexane : ethyl acetate = 2 : 1);

NMR (DMSO-d₆) : δ 12.29 (brs, 1H), 9.30 and 9.28 (brs x2, 1H), 8.40-8.30 (m, 1H), 7.98-7.90 (m, 1H), 7.88-7.80 (m, 1H), 7.65-7.38 (m, 5H), 7.18-7.02 (m, 3H), 4.80-4.64 (m, 1H), 2.62-2.50 (m, 1H), 2.20-2.05 (m, 1H), 1.90-0.78 (m, 12H), 0.60-0.20 (m, 1H).

Example 2(19)

2-[4-fluoro-2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0092]




TLC: Rf 0.62 (chloroform : methanol = 10 : 1);

NMR(DMSO-d₆) : δ 9.73 (s, 1H), 8.19 (m, 1H), 8.00-7.82 (m, 3H), 7.60-7.32 (m, 7H), 7.02-6.94 (m, 3H), 4.73 (q, J = 6.9 Hz, 1H), 4.33 (d, J = 16.8 Hz, 1H), 4.27 (d, J = 16.8 Hz, 1H), 1.54 (d, J = 6.9 Hz, 3H).

Example 2(20)

2-[4-trifluoromethyl-2-[2-(1-naphthyl)propanoylamino]phenylmethyl]benzoic acid

[0093]




TLC: Rf 0.66 (chloroform : methanol = 10 : 1);

NMR(DMSO-d₆) : δ 9.90 (s, 1H), 8.22 (m, 1H), 8.02-7.85 (m, 4H), 7.63-7.36 (m, 7H), 7.07 (m, 2H), 4.78 (q, J = 6.9 Hz, 1H), 4.43 (d, J = 16.2 Hz, 1H), 4.36 (d, J = 16.2 Hz, 1H), 1.58 (d, J = 6.9 Hz, 3H).

Example 2(21)

2-[4-methyl-2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0094]




TLC: Rf 0.73 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 9.52 (s, 1H), 8.20 (m, 1H), 7.93-7.74 (m, 3H), 7.55-7.22 (m, 7H), 6.88 (m, 2H), 6.78 (d, J = 7.8 Hz, 1H), 4.61 (q, J = 6.9 Hz, 1H), 4.23 (d, J = 16.5 Hz, 1H), 4.16 (d, J = 16.5 Hz, 1H), 2.22 (s, 3H), 1.46 (d, J = 6.9 Hz, 3H).

Example 2(22)

(dl)-trans-2-[2-(2-phenylcyclopropylcarbonylamino)phenyl methyl]benzoic acid

[0095]




TLC: Rf 0.57 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 9.66 (s, 1H), 7.79 (dd, J = 7.8, 1.2 Hz, 1H), 7.58-6.83 (m, 12H), 4.33 (s, 2H), 2.33-2.12 (m, 2H), 1.45-1.21 (m, 2H).

Example 2(23)

2-[2-(2-(4-benzyloxyphenyl)acetyl amino]phenyl methyl] benzoic acid

[0096]




TLC: Rf 0.54 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆) : δ 9.47 (s, 1H), 7.83 (dd, J = 8.7, 1.8 Hz, 1H), 7.50-6.86 (m, 16H), 5.05 (s, 2H), 4.30 (s, 2H), 3.51 (s, 2H).

Example 2(24)

2-[2-(9-oxofluoren-4-ylcarbonylamino)phenyl methyl]benzoic acid

[0097]




TLC: Rf 0.57 (chloroform : methanol = 9 : 1);
NMR(DMSO-d₆) : δ 10.3 (s, 1H), 7.83-6.98 (m, 15H), 4.42 (s, 2H).

Example 2(25)

2-[2-[5-(4-chlorophenyl)-2-methylfuran-3-ylcarbonylamino] phenylmethyl]benzoic acid

[0098]




TLC: Rf 0.55 (chloroform : methanol = 10 : 1) ;
NMR(DMSO-d₆) : δ 9.46 (s, 1H), 7.80 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.44-7.37 (m, 2H), 7.32-7.04 (m, 5H), 6.95 (m, 1H), 4.38 (s, 2H), 2.55 (s, 3H).

Example 2(26)

2-[3-[2-(1-naphthyl)propanoylamino]pyridin-2-ylmethyl] benzoic acid

[0099]




TLC: Rf 0.20 (chloroform : methanol = 10 : 1);

NMR(DMSO-d₆) : δ 9.86 (s, 1H), 8.18 (d, J = 7.5 Hz, 1H), 7.97-7.77 (m, 4H), 7.58-7.30 (m, 7H), 7.00-6.93 (m, 2H), 4.71 (q, J = 6.9 Hz, 1H), 4.35 (d, J = 16.5 Hz, 1H), 4.28 (d, J = 16.5 Hz, 1H), 1.50 (d, J = 6.9 Hz, 3H).Example 2(27)

2-[4-cyano-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0100]




TLC: Rf 0.50 (chloroform : methanol = 10 : 1);

NMR(DMSO-d₆) : δ 10.1 (s, 1H), 8.42-8.13 (m, 3H), 7.96-7.78 (m, 3H), 7.63-7.30 (m, 7H), 6.91 (d, J = 6.6 Hz, 1H), 4.68 (q, J = 6.9 Hz, 1H), 4.61 (s, 2H), 1.46 (d, J = 6.9 Hz, 3H).

Example 2(28)

4-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl]nicotinic acid

[0101]




TLC: Rf 0.38 (chloroform : methanol = 4 : 1);

NMR(DMSO- d_6): δ 13.36 (br, 1H), 9.60 (s, 1H), 8.90 (s, 1H), 8.40 (d, J = 5.1 Hz, 1H), 8.15 (m, 1H), 7.89 (m, 1H), 7.77 (d, J = 7.5 Hz, 1H), 7.52-7.35 (m, 5H), 7.23 (m, 1H), 7.11 (m, 1H), 7.01 (m, 1H), 6.75 (d, J = 5.1 Hz, 1H), 4.56 (q, J = 6.9 Hz, 1H), 4.33 (d, J = 17.1 Hz, 1H), 4.27 (d, J = 17.1 Hz, 1H), 1.42 (d, J = 6.9 Hz, 3H).

Example 2(29)

2-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl]nicotinic acid

[0102]




TLC: Rf 0.36 (chloroform : methanol = 9 : 1);

NMR(DMSO- d_6): δ 13.45 (br, 1H), 10.30 (s, 1H), 8.25 (d, J = 8.1 Hz, 1H), 8.08 (dd, J = 7.8, 1.8 Hz, 1H), 8.02 (dd, J = 4.8, 1.8 Hz, 1H), 7.91 (m, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.68-7.44 (m, 5H), 7.23 (dd, J = 7.8, 4.8 Hz, 1H), 7.18-7.10 (m, 2H), 6.96 (m, 1H), 4.70 (q, J = 6.9 Hz, 1H), 4.19 (d, J = 14.4 Hz, 1H), 4.12 (d, J = 14.4 Hz, 1H), 1.63 (d, J = 6.9 Hz, 3H).

Example 2(30)

2-[3-[2-(1-naphthyl)propanoylamino]pyridin-4-ylmethyl] benzoic acid

[0103]




TLC: Rf 0.50 (chloroform : methanol = 6 : 1);

NMR(DMSO-d₆): δ 10.3 (s, 1H), 8.98 (s, 1H), 8.38 (d, J = 6.0 Hz, 1H), 8.23 (d, J = 8.1 Hz, 1H), 7.93 (m, 2H), 7.83 (d, J = 7.8 Hz, 1H), 7.60-7.39 (m, 6H), 7.17 (d, J = 7.8 Hz, 1H), 7.07 (d, J = 5.4 Hz, 1H), 4.84 (q, J = 6.9 Hz, 1H), 4.46 (d, J = 17.1 Hz, 1H), 4.38 (d, J = 17.1 Hz, 1H), 1.56 (d, J = 6.9 Hz, 3H).

Reference Example 5

2-(4-cyano-2-nitrophenylmethyl)benzoic acid methyl ester

[0104]



[0105] Under atmosphere of argon, to a solution of zinc powder (1.89 g) in anhydrous THF (15 ml) was added di-bromoethane (116 ul) and the mixture was stirred for five minutes at 60 °C. To the reaction mixture was added a solution of 2-bromomethylbenzoic acid methyl ester (4.42 g) in anhydrous THF (15 ml) over a period of 30 minutes at 0 °C and the mixture was stirred for 2 hours at the temperature to give a 2-carbomethoxybenzylzinc (II) bromide (benzyl zinc) solution.

[0106] Under atmosphere of argon, to a solution of 1-cyano-3-nitro-4-iodobenzene (2.00 g), bis(dibenzylideneacetone)palladium (42 mg) and 1,1'-bis (diphenylphosphino) ferrocene (41 mg) in anhydrous THF (10 ml) was added the above prepared benzyl zinc solution dropwise at room temperature and the mixture was stirred for 2 hours at 60 °C. To the reaction mixture was added a saturated aqueous solution of ammonium chloride at 0 °C and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride and was dried over magnesium sulfate and was concentrated. The residue was purified by column chromatography on silica gel (n-hexane : ethyl acetate = 5 : 1) to give the title compound (809 mg) having the following physical data.

TLC: Rf 0.61 (n-hexane : ethyl acetate = 2 : 1);


NMR(CDCl₃): δ 8.25 (d, J = 1.8 Hz, 1H), 8.05 (dd, J = 7.8, 1.5 Hz, 1H), 7.66 (dd, J = 8.0, 1.8 Hz, 1H), 7.54 (dt, J =

7.8, 1.5 Hz, 1H), 7.42 (dt, $J = 7.8, 1.5$ Hz, 1H), 7.23 (d, $J = 7.8$ Hz, 1H), 7.10 (d, $J = 8.0$ Hz, 1H), 4.69 (s, 2H), 3.76 (s, 3H).

Reference Example 6

2- (2-amino-4-cyanophenylmethyl)benzoic acid methyl ester

[0107]



[0108] To a solution of the compound prepared in reference example 5 (705 mg) in acetic acid / water (7 ml / 0.7 ml) was added steel (664 mg) and the mixture was stirred for 20 minutes at 60 °C. To the reaction mixture was added water at 0 °C and was filtered over celite (brand name). The filtrate was washed with water, a saturated aqueous solution of sodium bicarbonate and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and was concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 6 : 1 ~ 4 : 1) to give the title compound (355 mg) having the following physical data.


TLC: Rf 0.40 (n-hexane : ethyl acetate = 2 : 1);

NMR(CDCl₃) : δ 7.93 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.44 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.32 (dt, $J = 7.7, 1.4$ Hz, 1H), 7.14 (d, $J = 7.8$ Hz, 1H), 7.02-6.94 (m, 2H), 6.89 (s, 1H), 4.25 (s, 2H), 4.13 (bs, 2H), 3.88 (s, 3H).

Example 3

2-[4-cyano-2-[4-methyl-2-(1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid methyl ester

[0109]



[0110] Under atmosphere of argon, the compound prepared in reference example 6 (213 mg) and pyridine (129 μ l) in anhydrous methylene chloride (2 ml) was added 4-methyl-2-(1-naphthyl)valeryl chloride (250 mg) in anhydrous methylene chloride (1 ml) at 0 °C and the mixture was stirred for 15 minutes at the temperature. To the reaction mixture was added a saturated aqueous solution of sodium bicarbonate at 0 °C and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride and was dried over sodium sulfate and was concentrated. The residue was purified by column chromatography on silica gel (n-hexane : ethyl acetate = 9 : 1 ~ 3 : 1) to give the title compound (371 mg) having the following physical data.

TLC: Rf 0.60 (n-hexane : ethyl acetate = 2 : 1);


NMR(CDCl₃) : δ 8.56 (bs, 1H), 8.07 (d, $J = 7.8$ Hz, 1H), 7.85 (m, 1H), 7.69 (d, $J = 7.8$ Hz, 1H), 7.58-7.45 (m, 2H), 7.37-7.21 (m, 6H), 7.18-7.05 (m, 2H), 6.87 (d, $J = 7.8$ Hz, 1H), 4.42 (dd, $J = 8.7, 5.4$ Hz, 1H), 4.10 (d, $J = 16$ Hz, 1H),

3.87 (d, J = 16 Hz, 1H), 3.73 (s, 3H), 2.17 (m, 1H), 1.75-1.59 (m, 2H), 1.01 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H).

Example 4

2-[4-cyano-2-[4-methyl-2- (1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid

[0111]



[0112] To a solution of the compound prepared in example 3 (365 mg) in THF / methanol (2 ml / 1 ml) was added 1N aqueous solution of sodium hydroxide (1 ml) and the mixture was stirred for 4 hours at room temperature. The reaction mixture was concentrated and the residue was diluted with ether and was extracted with water. The aqueous layer was neutralized with 1N hydrochloric acid and was extracted with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and was concentrated. The residue was purified by column chromatography on silica gel (chloroform ~ chloroform : methanol = 50 : 1) to give the title compound (313 mg) having the following physical data.

TLC: Rf 0.60 (chloroform : methanol = 9 : 1);

NMR (CDCl₃) : δ 8.51 (s, 1H), 8.03 (d, J = 7.8 Hz, 1H), 7.95 (s, 1H), 7.82 (m, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H), 7.53-7.40 (m, 2H), 7.36-7.06 (m, 6H), 6.79 (d, J = 7.5 Hz, 1H), 4.37 (t, J = 7.4 Hz, 1H), 4.09 (d, J = 16 Hz, 1H), 3.83 (d, J = 16 Hz, 1H), 2.18 (m, 1H), 1.80-1.54 (m, 2H), 0.98 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H).


Example 4(1) ~ Example 4(34)

[0113] By the same procedure as described in Reference Example 5 -> Reference Example 6 -> Example 3 -> Example 4 using the corresponding compounds, optionally followed by converting to known salts, the following compounds were given.

Example 4(1)

2-[2-(4-benzyloxyphenyl)propanoylamino]phenylmethyl] benzoic acid

[0114]




TLC: Rf 0.25 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃): δ 8.01-7.97 (m, 2H), 7.47 (brs, 1H), 7.43-7.23 (m, 8H), 7.07-7.04 (m, 4H), 6.93 (d, J = 7.8 Hz, 1H), 6.80 (d, J = 8.4 Hz, 2H), 5.00 (s, 2H), 4.15 (d, J = 17.3 Hz, 1H), 4.14 (d, J = 17.3 Hz, 1H), 3.58 (q, J = 7.2 Hz, 1H), 1.45 (d, J = 7.2 Hz, 3H).

Example 4(2)

2-[2-(2-(3-benzyloxyphenyl)propanoylamino]phenylmethyl] benzoic acid

[0115]




TLC: Rf 0.30 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃): δ 7.96 (d, J = 8.1 Hz, 2H), 7.61 (brs, 1H), 7.40-7.22 (m, 8H), 7.11-7.04 (m, 3H), 6.98 (d, J = 7.5 Hz, 1H), 6.86 (s, 1H), 6.80-6.75 (m, 2H), 4.96 (s, 2H), 4.15 (d, J = 16.5 Hz, 1H), 4.13 (d, J = 16.5 Hz, 1H), 3.61 (q, J = 7.2 Hz, 1H), 1.47 (d, J = 7.2 Hz, 3H).

Example 4(3)

2-[2-[2-(1-naphthyl)butanoylamino]phenylmethyl]benzoic acid

[0116]




TLC: Rf 0.45 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 8.02 (d, J = 7.5 Hz, 2H), 7.80-7.72 (m, 2H), 7.66 (d, J = 8.1 Hz, 1H), 7.56 (brs, 1H), 7.45-7.40 (m, 2H), 7.32-7.14 (m, 5H), 7.07-7.00 (m, 2H), 6.80 (d, J = 7.5 Hz, 1H), 4.13 (t, J = 7.2 Hz, 1H), 4.05 (d, J = 16.8 Hz, 1H), 3.87 (d, J = 16.8 Hz, 1H), 2.34-2.25 (m, 1H), 1.98-1.89 (m, 1H), 0.95 (t, J = 7.2 Hz, 3H).

Example 4(4)

2-[2-[2-(1-naphthyl)pentanoylamino]phenylmethyl]benzoic acid

[0117]




TLC: Rf 0.50 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 8.03 (d, J = 8.7 Hz, 2H), 7.81-7.77 (m, 1H), 7.73 (d, J = 6.6 Hz, 1H), 7.66 (d, J = 8.1 Hz, 1H), 7.57 (brs, 1H), 7.45-7.41 (m, 2H), 7.32-7.14 (m, 5H), 7.07-7.00 (m, 2H), 6.80 (d, J = 7.5 Hz, 1H), 4.23 (t, J = 7.4 Hz, 1H), 4.05 (d, J = 17.0 Hz, 1H), 3.87 (d, J = 17.0 Hz, 1H), 2.30-2.18 (m, 1H), 1.92-1.80 (m, 1H), 1.40-1.28 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H).

Example 4(5)

2-[2-[3-methyl-2-(1-naphthyl)butanoylamino]phenylmethyl] benzoic acid

[0118]




TLC: Rf 0.50 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 8.13 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.81-7.66 (m, 4H), 7.55 (d, J = 7.5 Hz, 1H), 7.47-7.39 (m, 2H), 7.36-7.17 (m, 4H), 7.04-7.03 (m, 2H), 6.90 (d, J = 7.5 Hz, 1H), 4.15 (d, J = 16.5 Hz, 1H), 4.02 (d, J = 16.5 Hz, 1H), 3.91 (d, J = 9.9 Hz, 1H), 2.62-2.50 (m, 1H), 1.13 (d, J = 6.6 Hz, 3H), 0.70 (d, J = 6.6 Hz, 3H).

Example 4(6)

2-[2-[2-(1,1'-biphenyl-2-yl)propanoylamino]phenylmethyl] benzoic acid

[0119]




TLC: Rf 0.40 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 8.07 (dd, J = 7.5, 1.5 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.40-6.96 (m, 15H), 6.87 (d, J = 7.5 Hz, 1H), 4.07 (s, 2H), 3.78 (q, J = 6.9 Hz, 1H), 1.44 (d, J = 6.9 Hz, 3H).

Example 4(7)

2-[2-[2-(1,1'-biphenyl-3-yl)propanoylamino]phenylmethyl] benzoic acid

[0120]




TLC: Rf 0.25 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 7.98 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 7.8 Hz, 1H), 7.66 (br s, 1H), 7.51-7.04 (m, 14H), 6.97 (d, J = 7.5 Hz, 1H), 4.20 (d, J = 16.5 Hz, 1H), 4.10 (d, J = 16.5 Hz, 1H), 3.71 (q, J = 7.2 Hz, 1H), 1.53 (d, J = 7.2 Hz, 3H).Example 4(8)

2-[2-[2-(4-phenoxyphenyl)propanoylamino]phenylmethyl] benzoic acid

[0121]




TLC: Rf 0.20 (n-hexane : ethyl acetate = 1 : 2);

NMR(CDCl₃) : δ 7.99 (d, J = 8.1 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.70 (br s, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.32-6.91 (m, 13H), 6.80 (d, J = 6.9 Hz, 1H), 4.17 (s, 2H), 3.61 (q, J = 7.2 Hz, 1H), 1.46 (d, J = 7.2 Hz, 3H).

Example 4(9)

2-[2-[2-[4-(2-phenylethoxy)phenyl]propanoylamino]phenyl methyl]benzoic acid

[0122]




TLC: Rf 0.40 (n-hexane : ethyl acetate = 1 : 3);

NMR(CDCl₃) : δ 7.99 (d, J = 8.1 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.42 (brs, 1H), 7.27-7.19 (m, 9H), 7.06-7.01 (m, 3H), 6.89 (d, J = 7.2 Hz, 1H), 6.70 (d, J = 8.4 Hz, 2H), 4.20-4.07 (m, 4H), 3.56 (q, J = 7.2 Hz, 1H), 3.06 (t, J = 6.9 Hz, 2H), 1.44 (d, J = 7.2 Hz, 3H).

Example 4(10)

2-[2-[2-[4-(3-phenylpropoxy)phenyl]propanoylamino]phenyl methyl]benzoic acid

[0123]




TLC: Rf 0.45 (n-hexane : ethyl acetate = 1 : 3);

NMR(CDCl₃) : δ 7.98 (d, J = 8.1 Hz, 2H), 7.45 (brs, 1H), 7.37 (dt, J = 1.5, 7.5 Hz, 1H), 7.31-7.18 (m, 8H), 7.06-7.03 (m, 3H), 6.92 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 8.4 Hz, 2H), 4.16 (d, J = 17.1 Hz, 1H), 4.14 (d, J = 17.1 Hz, 1H), 3.88 (t, J = 6.3 Hz, 2H), 3.57 (q, J = 7.2 Hz, 1H), 2.70 (t, J = 7.8 Hz, 2H), 2.12-2.02 (m, 2H), 1.44 (d, J = 7.2 Hz, 3H).

Example 4(11)

2-[2-[2-methoxy-2-(1-naphthyl)acetyl]amino]phenyl[methyl] benzoic acid

[0124]




TLC: Rf 0.30 (n-hexane : ethyl acetate = 1 : 3);

NMR(CDC_l₃) : δ 8.66 (brs, 1H), 8.17-8.12 (m, 2H), 8.04 (d, J = 8.1 Hz, 1H), 7.82-7.75 (m, 2H), 7.52-7.31 (m, 6H), 7.25-7.21 (m, 1H), 7.10-7.08 (m, 3H), 5.25 (s, 1H), 4.51 (s, 2H), 3.24 (s, 3H).Example 4(12)

2-[2-[2-(4-isobutylphenyl)propanoyl]amino]phenyl[methyl] benzoic acid

[0125]




TLC: Rf 0.55 (ethyl acetate);

NMR(CDC_l₃) : δ 8.02 (dd, J = 7.8, 1.2 Hz, 1H), 7.96 (d, J = 7.5 Hz, 1H), 7.50 (brs, 1H), 7.40 (dt, J = 1.5, 7.5 Hz, 1H), 7.33-7.21 (m, 2H), 7.10-6.98 (m, 7H), 4.12 (s, 2H), 3.62 (q, J = 6.9 Hz, 1H), 2.39 (d, J = 6.9 Hz, 2H), 1.81-1.72 (m, 1H), 1.48 (d, J = 6.9 Hz, 3H), 0.82 (d, J = 6.6 Hz, 6H).

Example 4(13)

2-[2-[4-methyl-2-(1-naphthyl)pentanoylamino]phenylmethyl] benzoic acid

[0126]




TLC: Rf 0.35 (n-hexane : ethyl acetate = 1 : 1);

NMR(CDCl₃) : δ 8.08-8.03 (m, 2H), 7.82-7.62 (m, 4H), 7.49-7.41 (m, 2H), 7.33-7.18 (m, 4H), 7.17-6.95 (m, 3H), 6.81 (d, J = 7.5 Hz, 1H), 4.34 (brt, 1H), 4.08 (d, J = 16.5 Hz, 1H), 3.84 (d, J = 16.5 Hz, 1H), 2.20-2.12 (m, 1H), 1.77-1.69 (m, 1H), 1.64-1.56 (m, 1H), 0.95 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H).

Example 4(14)

2-[2-[2-(1-naphthyl)hexanoylamino]phenylmethyl]benzoic acid

[0127]




TLC: Rf 0.34 (n-hexane : ethyl acetate = 1 : 1);

NMR(CDCl₃) : δ 8.04 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 7.0 Hz, 1H), 7.72-7.60 (m, 3H), 7.49-7.39 (m, 2H), 7.32-7.14 (m, 5H), 7.07-7.00 (m, 2H), 6.81 (d, J = 7.5 Hz, 1H), 4.21 (t, J = 7.5 Hz, 1H), 4.13 (d, J = 16.5 Hz, 1H), 3.86 (d, J = 16.5 Hz, 1H), 2.33-2.19 (m, 1H), 1.94-1.79 (m, 1H), 1.40-1.20 (m, 4H), 0.84 (t, J = 7.0 Hz, 3H).

Example 4(15)

2-[2-[2-(4-(4-phenylbutoxy)phenyl)propanoylamino]phenyl methyl]benzoic acid

[0128]




TLC: Rf 0.60 (ethyl acetate);

NMR (CDCl₃): δ 7.99 (t, J = 7.2 Hz, 2H), 7.45 (s, 1H), 7.37 (dt, J = 1.5, 7.5 Hz, 1H), 7.30-7.15 (m, 8H), 7.06-7.03 (m, 3H), 6.92 (d, J = 7.5 Hz, 1H), 6.69 (d, J = 8.4 Hz, 2H), 4.16 (d, J = 17.1 Hz, 1H), 4.15 (d, J = 17.1 Hz, 1H), 3.88 (m, 2H), 3.57 (q, J = 6.9 Hz, 1H), 2.66 (m, 2H), 1.77 (m, 4H), 1.44 (d, J = 6.9 Hz, 3H).

Example 4(16)

2-[2-[2(R)-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0129]




TLC: Rf 0.40 (ethyl acetate);

NMR(CDCl₃): δ 8.00 (d, J = 8.1 Hz, 2H), 7.82-7.76 (m, 2H), 7.66 (d, J = 7.5 Hz, 1H), 7.45-7.39 (m, 3H), 7.31-7.16 (m, 5H), 7.06-6.95 (m, 2H), 6.77 (d, J = 7.2 Hz, 1H), 4.40 (q, J = 7.2 Hz, 1H), 3.94 (d, J = 16.8 Hz, 1H), 3.81 (d, J = 16.8 Hz, 1H), 1.66 (d, J = 7.2 Hz, 3H).

Example 4(17)

2-[2-[2(S)-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid

[0130]




TLC: Rf 0.40 (ethyl acetate);

NMR(CDCl₃): δ 8.04-8.00 (m, 2H), 7.81-7.75 (m, 2H), 7.67 (d, J = 9.0 Hz, 1H), 7.47-7.42 (m, 3H), 7.28-7.16 (m, 5H), 7.06-6.97 (m, 2H), 6.79 (d, J = 7.8 Hz, 1H), 4.41 (q, J = 7.2 Hz, 1H), 3.96 (d, J = 16.8 Hz, 1H), 3.81 (d, J = 16.8 Hz, 1H), 1.65 (d, J = 7.2 Hz, 3H).

Example 4(18)

2-[4-cyano-2-[4-methyl-2-(1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid sodium salt

[0131]




TLC: Rf 0.60 (chloroform : methanol = 9 : 1);

NMR(DMSO-d₆): δ 8.63 (d, J = 8.4 Hz, 1H), 8.50 (s, 1H), 7.84 (m, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.65-7.36 (m, 8H), 6.98 (m, 2H), 6.87 (m, 1H), 5.16 (m, 1H), 4.61 (d, J = 14.4 Hz, 1H), 4.22 (d, J = 14.4 Hz, 1H), 1.60 (m, 2H), 1.31 (m, 1H), 0.84 (d, J = 6.3 Hz, 3H), 0.73 (d, J = 6.3 Hz, 3H).

Example 4(19)

2-[2-[2-ethoxy-2-(1-naphthyl)acetyl]amino]phenylmethyl] benzoic acid

[0132]




TLC: Rf 0.18 (n-hexane : ethyl acetate = 3 : 1);

NMR(CDCl₃) : δ 8.77 (brs, 1H), 8.22-8.17 (m, 2H), 8.06 (d, J = 7.8 Hz, 1H), 7.82-7.73 (m, 2H), 7.54-7.21 (m, 6H), 7.13-7.03 (m, 3H), 5.40 (s, 1H), 4.53 (brs, 2H), 3.49-3.35 (m, 2H), 1.03(t, J = 7.2 Hz, 3H).Example 4(20)

2-[2-[2-(1-naphthyl)heptanoyl]amino]phenylmethyl]benzoic acid

[0133]




TLC: Rf 0.19 (n-hexane : ethyl acetate = 3 : 1);

NMR (CDCl₃) : δ 8.09-7.98 (m, 2H), 7.80-7.72 (m, 2H), 7.65 (d, J = 6.9Hz, 1H), 7.52 (bs, 1H), 7.49-7.37 (m, 2H), 7.35-7.13 (m, 4H), 7.08-6.97 (m, 2H), 6.79 (d, J = 6.9 Hz, 1H), 4.19 (m, 1H), 4.02 (brd, J = 17.1 Hz, 1H), 3.88 (brd, J = 17.1 Hz, 1H), 2.25 (m, 1H), 1.87 (m, 1H), 1.60-1.10 (m, 5H), 0.88-0.78 (m, 4H).

Example 4(21)

2-[2-[4,4-dimethyl-2-(1-naphthyl)pentanoylamino]phenyl methyl]benzoic acid

[0134]




TLC: Rf 0.37 (n-hexane : ethyl acetate = 1 : 1);

NMR(CDCl₃) : δ 8.10-8.00 (m, 2H), 7.85 (brs, 1H), 7.80 (m, 1H), 7.63 (brd, J = 7.8 Hz, 1H), 7.52-7.38 (m, 3H), 7.34 (brd, J = 7.6 Hz, 1H), 7.30-7.17 (m, 3H), 7.13-7.02 (m, 3H), 6.83 (brd, J = 7.8 Hz, 1H), 4.22 (m, 1H), 4.16 (d, J = 16.5 Hz, 1H), 3.85 (d, J = 16.5 Hz, 1H), 2.53 (m, 1H), 1.58 (dd, J = 13.8, 3.6 Hz, 1H), 0.92 (s, 9H).

Example 4(22)

2-[2-[2-[4-(3-phenylpropyl)phenyl]propanoylamino]phenyl methyl]benzoic acid

[0135]




TLC: Rf 0.51 (chloroform : methanol = 10 : 1);

NMR (DMSO-d₆) : δ 9.41 (s, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.36-7.00 (m, 13H), 6.89 (d, J = 7.5 Hz, 2H), 4.22 (s, 2H), 3.80 (q, J = 6.9 Hz, 1H), 2.60-2.40 (m, 4H), 1.82 (m, 2H), 1.30 (d, J = 6.9 Hz, 3H).

Example 4(23)

2-[2-[2-(quinolin-5-yl)propanoylamino]phenylmethyl] benzoic acid

[0136]




TLC: Rf 0.25 (chloroform : methanol = 9 : 1);

NMR (CD₃OD) : δ 8.82 (dd, J = 4.2, 1.2 Hz, 1H), 8.63 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.66-7.50 (m, 5H), 7.24-7.18 (m, 2H), 7.14-7.09 (m, 3H), 6.87 (d, J = 7.5 Hz, 1H), 4.60 (q, J = 7.2 Hz, 1H), 4.25 (d, J = 16.5 Hz, 1H), 4.10 (d, J = 16.5 Hz, 1H), 1.56 (d, J = 7.2 Hz, 3H).

Example 4(24)

2-[2-[2-[4-[2-(3-pyridyl)ethoxy]phenyl]propanoylamino] phenylmethyl]benzoic acid hydrochloride

[0137]




TLC: Rf 0.56 (chloroform : methanol = 9 : 1);

NMR (DMSO-d₆) : δ 9.39 (brs, 1H), 8.84 (brs, 1H), 8.75 (d, J = 5.4 Hz, 1H), 8.42 (d, J = 8.0 Hz, 1H), 7.91 (dd, J = 8.0, 5.4 Hz, 1H), 7.79 (dd, J = 8.0, 1.2 Hz, 1H), 7.42-7.10 (m, 6H), 7.04 (m, 1H), 6.92-6.86 (m; 2H), 6.81 (d, J = 8.7 Hz, 2H), 4.25-4.20 (m, 2H), 4.22 (s, 2H), 3.77 (q, J = 6.9 Hz, 1H), 3.20 (t, J = 6.2 Hz, 2H), 1.28 (d, J = 6.9 Hz, 3H).

Example 4(25)

2-[2-[2-[4-(2-phenoxyethyl)phenyl]propanoylamino]phenyl methyl]benzoic acid

[0138]




TLC: Rf 0.15 (n-hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃) : δ 7.99 (dd, J = 7.5, 1.2 Hz, 1H), 7.95 (brd, J = 8.1 Hz, 1H), 7.55 (brs, 1H), 7.36 (m, 1H), 7.30-7.21 (m, 4H), 7.15-7.02 (m, 6H), 6.98-9.83 (m, 4H), 4.21-4.08 (m, 4H), 3.61 (q, J = 7.2 Hz, 1H), 3.01 (t, J = 6.9 Hz, 2H), 1.45 (d, J = 7.2 Hz, 3H).

Example 4(26)

2-[2-[4-methoxy-2-(1-naphthyl)butanoylamino]phenylmethyl] benzoic acid

[0139]




TLC: Rf 0.51 (chloroform : methanol = 10 : 1);

NMR(DMSO-d₆) : δ 9.69 (s, 1H), 8.30 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.74 (m, 1H), 7.59-7.19 (m, 6H), 7.15 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H), 4.69 (dd, J = 8.7, 5.1 Hz, 1H), 4.26 (d, J = 15.9 Hz, 1H), 4.18 (d, J = 15.9 Hz, 1H), 3.29 (s, 2H), 3.17 (s, 3H), 2.29 (m, 1H), 1.94 (m, 1H).

Example 4(27)

2-[2-[5-methyl-2-(1-naphthyl)hexanoylamino]phenylmethyl] benzoic acid

[0140]




TLC: Rf 0.69 (chloroform : methanol = 10 : 1);

NMR (CDCl₃) : δ 8.04 (d, J = 7.8 Hz, 2H), 7.80 (m, 1H), 7.74-7.64 (m, 2H), 7.61 (bs, 1H), 7.45 (m, 2H), 7.34-7.12 (m, 5H), 7.02 (m, 2H), 6.82 (d, J = 7.8 Hz, 1H), 4.17 (t, J = 7.2 Hz, 1H), 4.04 (d, J = 16.8 Hz, 1H), 3.87 (d, J = 16.8 Hz, 1H), 2.25 (m, 1H), 1.87 (m, 1H), 1.54 (m, 1H), 1.28 (m, 1H), 1.15 (m, 1H), 0.86 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 6.9 Hz, 3H).

Example 4(28)

5-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl]oxazol-4-carboxylic acid

[0141]




TLC: Rf 0.26 (chloroform : methanol = 9 : 1);

NMR (DMSO-d₆) : δ 13.1 (br, 1H), 9.69 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.24 (s, 1H), 7.93 (dd, J = 8.0, 1.8 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.60-7.45 (m, 4H), 7.29 (dd, J = 8.0, 1.2 Hz, 1H), 7.21 (m, 1H), 7.12 (m, 1H), 7.03 (dd, J = 8.0, 1.2 Hz, 1H), 4.65 (q, J = 7.2 Hz, 1H), 4.33 (d, J = 16.5 Hz, 1H), 4.26 (d, J = 16.5 Hz, 1H), 1.56 (d, J = 7.2 Hz, 3H).

Example 4(29)

2-[2-[2-[4-(2-phenylethylthio)phenyl]propanoylamino] phenylmethyl]benzoic acid

[0142]




TLC: Rf 0.45 (chloroform : methanol = 9 : 1);

NMR (200 MHz, CDCl₃) : δ 7.98-7.95 (m, 2H), 7.63 (s, 1H), 7.42-6.96 (m, 15H), 4.18 (d, J = 16.9 Hz, 1H), 4.16 (d, J = 16.9 Hz, 1H), 3.60 (q, J = 7.2 Hz, 1H), 3.16-3.07 (m, 2H), 2.92-2.84 (m, 2H), 1.45 (d, J = 7.2 Hz, 3H).Example 4(30)

2-[2-[3-methoxy-2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid

[0143]




TLC: Rf 0.55 (chloroform : methanol = 10 : 1);

NMR (DMSO-d₆) : δ 9.77 (s, 1H), 8.34 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.80-7.72 (m, 1H), 7.66-7.40 (m, 5H), 7.36-7.21 (m, 2H), 7.17 (t, J = 7.2 Hz, 1H), 7.06 (t, J = 7.2 Hz, 1H), 6.93 (d, J = 7.2 Hz, 1H), 6.88 (d, J = 7.2 Hz, 1H), 4.90 (dd, J = 9.0, 4.8 Hz, 1H), 4.27 (s, 2H), 4.00 (t, J = 9.0 Hz, 1H), 3.63 (dd, J = 9.0, 4.8 Hz, 1H), 3.29 (s, 3H).

Example 4(31)

2-[4-ethoxy-2-[4-methyl-2-(1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid

[0144]




TLC: Rf 0.58 (chloroform : methanol = 10 : 1);

NMR (DMSO- d_6) : δ 9.59 (s, 1H), 8.34 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 6.9 Hz, 1H), 7.69-7.43 (m, 4H), 7.33-7.21 (m, 2H), 7.12 (s, 1H), 6.90 (d, J = 7.8 Hz, 1H), 6.84 (d, J = 7.2 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 4.65 (m, 1H), 4.30 (d, J = 16.5 Hz, 1H), 4.17 (d, J = 16.5 Hz, 1H), 3.98 (q, J = 6.9 Hz, 1H), 1.95 (m, 1H), 1.62-1.40 (m, 2H), 1.32 (t, J = 6.9 Hz, 3H), 0.96 (d, J = 6.0 Hz, 3H), 0.85 (d, J = 6.0 Hz, 3H).

Example 4(32)

2-[4-isopropoxy-2-[4-methyl-2-(1-naphthyl)pentanoyl amino]phenylmethyl]benzoic acid

[0145]




TLC: Rf 0.59 (chloroform : methanol = 10 : 1);

NMR (CDCl₃) : δ 8.03 (d, J = 7.2 Hz, 1H), 7.86-7.75 (m, 2H), 7.70-7.59 (m, 3H), 7.50-7.39 (m, 2H), 7.30-7.08 (m, 4H), 6.92 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.58 (dd, J = 8.4, 2.4 Hz, 1H), 4.56 (m, 1H), 4.32 (t, J = 7.2 Hz, 1H), 4.01 (d, J = 16.8 Hz, 1H), 3.78 (d, J = 16.8 Hz, 1H), 2.14 (m, 1H), 1.73 (m, 1H), 1.59 (m, 1H), 1.32 (d, J = 6.3 Hz, 6H), 0.94 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H).

Example 4(33)

5-[2-[4-methyl-2-(1-naphthyl)pentanoylamino]phenylmethyl] oxazol-4-carboxylic acid

[0146]




TLC: Rf 0.40 (chloroform : methanol = 9 : 1);

NMR (CDCl₃) : δ 8.31 (d, J=8.4 Hz, 1H), 8.08 (s, 1H), 7.89-7.65 (m, 4H), 7.60-7.40 (m, 4H), 7.28-7.18 (m, 2H), 7.05 (t, J = 7.2 Hz, 1H), 4.62 (t, J = 7.8 Hz, 1H), 4.03 (d, J = 16 Hz, 1H), 3.92 (d, J = 16 Hz, 1H), 2.36 (m, 1H), 1.92 (m, 1H), 1.69 (m, 1H), 1.03 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H).

Example 4(34)

2-[4-methoxy-2-[4-methyl-2-(1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid

[0147]




TLC: Rf 0.48 (chloroform : methanol = 10 : 1);

NMR (CDCl₃) : δ 8.04 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 2.7 Hz, 1H), 7.83-7.72 (m, 2H), 7.69-7.56 (m, 2H), 7.46 (m, 2H), 7.30-7.17 (m, 3H), 7.11 (m, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.60 (dd, J = 8.4, 2.4 Hz, 1H), 4.34 (t, J = 7.2 Hz, 1H), 4.03 (d, J = 16.8 Hz, 1H), 3.81 (s, 3H), 3.79 (d, J = 16.8 Hz, 1H), 2.14 (m, 1H), 1.72 (m, 1H), 1.60 (m, 1H), 0.95 (d, J = 6.3 Hz, 3H), 0.88 (d, J = 6.3 Hz, 3H).

Example 5

2-[2-[2-[4-[2-(pyridin-2-yl)ethoxy]phenyl]propanoylamino] phenylmethyl]benzoic acid

[0148]




TLC: Rf 0.45 (chloroform : methanol = 9 : 1);

NMR (CDCl₃) : δ 8.67 (d, J = 4.5 Hz, 1H), 8.26 (dd, J = 6.0, 3.3 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 7.81 (dt, J = 1.5 Hz, 1H), 7.40-7.28 (m, 5H), 7.10-7.07 (m, 2H), 6.86-6.77 (m, 5H), 6.67 (dd, J = 5.4, 3.6 Hz, 1H), 4.48 (t, J = 6.9 Hz, 2H), 4.04 (s, 2H), 3.52-3.40 (m, 3H), 1.39 (d, J = 7.2 Hz, 3H).

Example 5(1)

2-[2-[2-[4-[2-(pyridin-4-yl)ethoxy]phenyl]propanoylamino] phenylmethyl]benzoic acid

[0149]




TLC: Rf 0.35 (chloroform : methanol = 9 : 1) ;

NMR (200 MHz, CDCl₃) : δ 8.70 (s, 1H), 8.57 (br s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.99 (dd, J = 6.1 Hz, 1H), 7.41-7.01 (m, 11H), 6.68 (d, J = 8.8 Hz, 2H), 4.46 (d, J = 16.1 Hz, 1H), 4.20 (t, J = 6.2 Hz, 2H), 4.11 (d, J = 16.1 Hz, 1H), 3.62 (q, J = 7.0 Hz, 1H), 3.08 (t, J = 6.2 Hz, 2H), 1.34 (d, J = 7.0 Hz, 3H).

Example 5(2)

2-[4-cyano-2-(4-methyl-2-phenylpentanoylamino)phenyl methyl]benzoic acid

[0150]




TLC: Rf 0.34 (chloroform : methanol = 9 : 1);

NMR (CDCl₃) : δ 8.47 (s, 1H), 8.20 (s, 1H), 7.97 (brd, J = 6.9 Hz, 1H), 7.43 (dt, J = 7.8 Hz, 1.8 Hz, 1H), 7.36-7.14 (m, 8H), 7.03 (d, J = 7.8 Hz, 1H), 4.21 (s, 2H), 3.57 (t, J = 7.8 Hz, 1H), 2.10-1.30 (m, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H).

Example 5(3)

2-[2-[2-(4-pentylphenyl)propanoylamino]phenylmethyl] benzoic acid

[0151]



TLC: Rf 0.39 (chloroform : methanol = 19 : 1);

NMR (CDCl₃) : δ 8.01 (d, J = 7.8 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.50 (bs, 1H), 7.44-7.20 (m, 3H), 7.11-6.93 (m, 7H), 4.16 (d, J = 17 Hz, 1H), 4.12 (d, J = 17 Hz, 1H), 3.61 (q, J = 7.2 Hz, 1H), 2.51 (m, 2H), 1.47 (d, J = 7.2 Hz, 3H), 1.62-1.19 (m, 6H), 0.86 (t, J = 6.9 Hz, 3H).

[Formulation Example]


Formulation Example 1

[0152] The following components were admixed by conventional techniques and punched out to give 100 tablets each containing 5 mg of active ingredient.


· 2-[2-(1-naphthyl)propanoylamino]phenylmethyl]benzoic acid	500 mg
· calcium carboxymethylcellulose	200 mg
· magnesium stearate	100 mg
· microcrystalline cellulose	9.2 g

Claims

1. A benzoic acid derivative of formula (I)



, wherein



are each independently, C3~7 carbocyclic ring or 5~7 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen atom,

D is C1-4 alkylene, oxygen or sulfur atom,

G is oxygen or sulfur,

E is a bond, oxygen, sulfur, C1-4 alkylene, C1-4 alkoxy or C1-4 oxyalkyl,

R¹ is hydroxy, -OR⁹ or -NR¹⁰R¹¹, wherein R⁹ is C1-6 alkyl, and R¹⁰ and R¹¹ are each independently, hydrogen atom or C1-6 alkyl, R² and R³ are each independently, C1-4 alkyl, C1-4 alkoxy, halogen atom, trihalomethyl, cyano or nitro,

R⁴ is hydrogen or C1-6 alkyl,

R⁵ is a bond, C1-6 alkylene, C1-6 alkylene substituted with C1-4 alkoxy, or C3-5 cycloalkylene,

R⁶ is C5~15 carbocyclic ring or 5-15 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen,

R⁷ is hydrogen, C1-8 alkyl, C5~7 carbocyclic ring or 5-15 membered heterocyclic ring containing nitrogen, sulfur and/or oxygen,

m and n are each independently, 0, 1, 2 or 3.

The rings represented by R⁶ and R⁷ may be substituted with C1-4 alkyl, C1-4 alkoxy, halogen, trihalomethyl, nitro, cyano or oxo,

with proviso that 2-[2-(benzoylamino)phenylmethyl]benzoic acid is excluded, or a non-toxic salt thereof.

2. The benzoic acid derivative according to claim 1, wherein A is benzene ring, pyridine ring, thiophene ring or cyclohexane ring, or a non-toxic salt thereof.
3. The benzoic acid derivative according to claim 1, wherein B is benzene ring, pyridine ring, thiophene ring or cyclohexane ring, or a non-toxic salt thereof.
4. The benzoic acid derivative according to claim 1, wherein D is methylene, or a non-toxic salt thereof.

5. The benzoic acid derivative according to claim 1, wherein D is oxygen atom, or a non-toxic salt thereof.
6. The benzoic acid derivative according to claim 1, wherein D is sulfur atom, or a non-toxic salt thereof.
7. The benzoic acid derivative according to claim 1, wherein R⁵ is a bond, or a non-toxic salt thereof.
8. The benzoic acid derivative according to claim 1, wherein R⁵ is branched C1~6 alkylene, or a non-toxic salt thereof.
9. The benzoic acid derivative according to claim 1, wherein R⁵ is C3~5 cycloalkylene, or a non-toxic salt thereof.
10. The benzoic acid derivative according to claim 1, wherein -R⁶-E-R⁷ is optionally substituted naphthyl, diphenyl, phenyl, tetrahydroquinolyl, benzyloxyphenyl, phenylfuryl or fluorenyl, or a non-toxic salt thereof.
11. The benzoic acid derivative according to claim 1, which is selected from

- (1) 2-[5-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (2) 2-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl] benzoic acid,
- (3) 2-[2-[2-(2-naphthyl)propanoylamino]phenylmethyl] benzoic acid,
- (4) 2-[2-[2-(4-pentylphenyl)propanoylamino]phenylthio] benzoic acid,
- (5) 2-[2-[2-(4-biphenyl)propanoylamino]phenylmethyl] benzoic acid,
- (6) 2-[2-[2-(1,2,3,4-tetrahydroquinolin-1-yl)propanoyl amino]phenylmethyl]benzoic acid,
- (7) 2-[3-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (8) 2-[5-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (9) 2-[2-[2-(1-naphthyl)acetylamino]phenylmethyl]benzoic acid,
- (10) 2-[2-[2-(1-naphthyl)carbonylamino]phenylmethyl] benzoic acid,
- (11) 2-[3-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (12) 2-[4-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (13) 2-[4-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (14) 2-[6-chloro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (15) 2-[6-methoxy-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (16) 2-[4-[2-(1-naphthyl)propanoylamino]pyridin-3-yl methyl]benzoic acid,
- (17) 2-[2-[2-(1-naphthyl)propanoylamino]phenoxy]benzoic acid,
- (18) 3-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl] thiophen-2-carboxylic acid,
- (19) (dl)-trans-2-[2-[2-(1-naphthyl)propanoylamino]phenyl methyl]cyclohexanecarboxylic acid,
- (20) 2-[4-fluoro-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (21) 2-[4-trifluoromethyl-2-[2-(1-naphthyl)propanoyl amino]phenylmethyl]benzoic acid,
- (22) 2-[4-methyl-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (23) (dl)-trans-2-[2-(2-phenylcyclopropylcarbonylamino) phenylmethyl]benzoic acid,
- (24) 2-[2-[2-(4-benzyloxyphenyl)acetylamino]phenylmethyl] benzoic acid,
- (25) 2-[2-(9-oxofluoren-4-ylcarbonylamino)phenylmethyl] benzoic acid,
- (26) 2-[2-[5-(4-chlorophenyl)-2-methylfuran-3-ylcarbonyl amino]phenylmethyl]benzoic acid,
- (27) 2-[3-[2-(1-naphthyl)propanoylamino]pyridin-2-yl methyl]benzoic acid,
- (28) 2-[4-cyano-2-[2-(1-naphthyl)propanoylamino]phenyl methyl]benzoic acid,
- (29) 4-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl] nicotinic acid,
- (30) 2-[2-[2-(1-naphthyl)propanoylamino]phenylmethyl] nicotinic acid,
- (31) 2-[3-[2-(1-naphthyl)propanoylamino]pyridin-4-yl methyl]benzoic acid,

or a methyl ester thereof or a non-toxic salt thereof.


12. The benzoic acid according to claim 1, which is selected from

- (1) 2-[4-cyano-2-[4-methyl-2-(1-naphthyl)pentanoylamino] phenylmethyl]benzoic acid,
- (2) 2-[2-[2-(4-benzyloxyphenyl)propanoylamino]phenyl methyl]benzoic acid,
- (3) 2-[2-[2-(3-benzyloxyphenyl)propanoylamino]phenyl methyl]benzoic acid,
- (4) 2-[2-[2-(1-naphthyl)butanoylamino]phenylmethyl] benzoic acid,
- (5) 2-[2-[2-(1-naphthyl)pentanoylamino]phenylmethyl] benzoic acid,
- (6) 2-[2-[3-methyl-2-(1-naphthyl)butanoylamino]phenyl methyl]benzoic acid,
- (7) 2-[2-[2-(1,1'-biphenyl-2-yl)propanoylamino]phenyl methyl]benzoic acid,


- (8) 2-[2-[2-(1,1'-biphenyl-3-yl)]propanoylamino]phenyl methyl]benzoic acid,
 (9) 2-[2-[2-(4-phenoxyphenyl)]propanoylamino]phenyl methyl]benzoic acid,
 (10) 2-[2-[2-[4-(2-phenylethoxy)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (11) 2-[2-[2-[4-(3-phenylpropoxy)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (12) 2-[2-[2-methoxy-2-(1-naphthyl)]acetylamino]phenyl methyl]benzoic acid,
 (13) 2-[2-[2-(4-isobutylphenyl)]propanoylamino]phenyl methyl]benzoic acid,
 (14) 2-[2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenyl methyl]benzoic acid,
 (15) 2-[2-[2-(1-naphthyl)]hexanoylamino]phenylmethyl]benzoic acid,
 (16) 2-[2-[2-[4-(4-phenylbutoxy)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (17) 2-[2-[2(R)-(1-naphthyl)]propanoylamino]phenylmethyl]benzoic acid,
 (18) 2-[2-[2(S)-(1-naphthyl)]propanoylamino]phenylmethyl]benzoic acid,
 (19) 2-[4-cyano-2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenylmethyl]benzoic acid,
 (20) 2-[2-[2-ethoxy-2-(1-naphthyl)]acetylamino]phenylmethyl]benzoic acid,
 (21) 2-[2-[2-(1-naphthyl)]heptanoylamino]phenylmethyl]benzoic acid,
 (22) 2-[2-[4,4-dimethyl-2-(1-naphthyl)]pentanoylamino]phenylmethyl]benzoic acid,
 (23) 2-[2-[2-[4-(3-phenylpropyl)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (24) 2-[2-[2-(quinolin-5-yl)]propanoylamino]phenylmethyl]benzoic acid,
 (25) 2-[2-[2-[4-[2-(3-pyridyl)ethoxy]phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (26) 2-[2-[2-[4-(2-phenoxyethyl)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (27) 2-[2-[4-methoxy-2-(1-naphthyl)]butanoylamino]phenyl methyl]benzoic acid,
 (28) 2-[2-[5-methyl-2-(1-naphthyl)]hexanoylamino]phenyl methyl]benzoic acid,
 (29) 5-[2-[2-(1-naphthyl)]propanoylamino]phenylmethyl]oxazol-4-carboxylic acid,
 (30) 2-[2-[2-[4-(2-phenylethylthio)phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (31) 2-[2-[3-methoxy-2-(1-naphthyl)]propanoylamino]phenyl methyl]benzoic acid,
 (32) 2-[4-ethoxy-2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenylmethyl]benzoic acid,
 (33) 2-[4-isopropoxy-2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenylmethyl]benzoic acid,
 (34) 5-[2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenyl methyl]oxazol-4-carboxylic acid,
 (35) 2-[4-methoxy-2-[4-methyl-2-(1-naphthyl)]pentanoylamino]phenylmethyl]benzoic acid,
 (36) 2-[2-[2-[4-[2-(pyridin-2-yl)ethoxy]phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (37) 2-[2-[2-[4-[2-(pyridin-4-yl)ethoxy]phenyl]]propanoylamino]phenylmethyl]benzoic acid,
 (38) 2-[4-cyano-2-(4-methyl-2-phenyl)pentanoylamino]phenyl methyl]benzoic acid,
 (39) 2-[2-[2-(4-pentylphenyl)]propanoylamino]phenylmethyl]benzoic acid,

or a methyl ester thereof or a non-toxic salt thereof.

13. A process for the preparation of a benzoic acid derivative of formula (Ia)




, wherein all symbols have the same meaning as above, **characterized by** subjecting to hydrolysis under alkaline conditions the compound of formula (Ib)




15 , wherein R²⁰ is C1-6 alkyl and the other symbols have the same meanings as defined in claim 1.

14. A process for the preparation of benzoic acid derivative of formula (Ic)



30 , wherein all symbols have the same meaning as defined in claim 1, **characterized by** subjecting to amidation reaction the compound of formula (Ia)




45 , wherein all symbols have the same meaning as defined in claim 1, and the compound of formula




55 , wherein all symbols have the same meaning as defined in claim 1.


15. A process for the preparation of the benzoic acid of formula (Ib)



15 , wherein R²⁰ is C1-6 alkyl and the other symbols have the same meaning as defined in claim 1, **characterized by** subjecting to a reaction the compound of formula (III)



30 , wherein all symbols have the same meaning as defined in claim 1, and the compound of formula (IV)



40 , wherein all symbols have the same meaning as defined in claim 1.

- 45
16. A pharmaceutical agent comprising the benzoic acid derivative of formula (I) described in claim 1 or a non-toxic salt thereof as active ingredient.
 17. An EP₄ receptor antagonist comprising the benzoic acid derivative of formula (I) described in claim 1 or a non-toxic salt thereof as active ingredient.
 18. An agent for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc., comprising the benzoic acid derivative of formula (I) described in claim 1 or a non-toxic salt thereof as active ingredient.
- 50
- 55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01263

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁷ C07C233/29, 233/55, 255/60, 231/12, 231/02, 253/30, 323/63, 323/62, 319/20, C07D215/06, 213/75, 333/40, 213/80, 263/34, 215/12, A61K31/196, 31/47, 31/44, 31/381, 31/421, 31/4402, 31/4409, 31/277, A61P43/00, 19/00, 35/00, 37/06, 37/08, 11/06, 17/00, 1/02, 25/00, 25/28, 11/00, 1/16, 13/12, 9/10, 17/02, 25/20, 7/02 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl. ⁷ C07C233/29, 233/55, 255/60, 231/12, 231/02, 253/30, 323/63, 323/62, 319/20, C07D215/06, 213/75, 333/40, 213/80, 263/34, 215/42, A61K31/196, 31/47, 31/44, 31/381, 31/421, 31/4402, 31/4409, 31/277, A61P43/00, 19/00, 35/00, 37/06, 37/08, 11/06, 17/00, 1/02, 25/00, 25/28, 11/00, 1/16, 13/12, 9/10, 17/02, 25/20, 7/02 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), CAOLD (STN), REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, 5447957, A (SmithKline Beecham Corp.), 05 September, 1995 (05.09.95), Column 17, lines 54 to 56 & WO, 95/33460, A1	1-3, 5, 7, 10, 16 4, 6, 8, 9, 11-15, 17, 18
A	DE, 2510260, A1 (Bayer AG), 23 September, 1976 (23.09.76) & JP, 51-115456, A & GB, 1500839, A	1-18
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 17 April, 2001 (17.04.01)		Date of mailing of the international search report 01 May, 2001 (01.05.01)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.